A Study of Revumenib in Combination With Intensive Chemotherapy in Participants With Acute Myeloid Leukemias
Public ClinicalTrials.gov record NCT06226571. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1, Open-label, Dose-escalation, and Dose-expansion Study to Evaluate Safety, Tolerability, and Clinical Activity of Revumenib in Combination With Intensive Chemotherapy in Participants With Newly Diagnosed Acute Myeloid Leukemias Harboring Alterations in Lysine-specific Methyltransferase 2A (KMT2A/MLL), Nucleophosmin 1 (NPM1), and Nucleoporin 98 (NUP98) Genes
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and clinical activity of revumenib in combination with intensive chemotherapy in participants with newly diagnosed acute myeloid leukemia (AML) harboring alterations in KMT2A, NPM1, or NUP98 genes.
Study identification
- NCT ID
- NCT06226571
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 96 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 75 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 21, 2024 (Actual)
- Primary completion
- Feb 2027 (Estimated)
- Completion
- Feb 2027 (Estimated)
- Last update posted
- Sep 16, 2026
2024 – 2027
United States locations
- U.S. sites
- 28
- U.S. states
- 19
- U.S. cities
- 26
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| City of Hope | Goodyear | Arizona | 85338 | — |
| UCLA Medical Hematology | Burbank | California | 91505 | — |
| City of Hope Medical Center | Duarte | California | 91010 | — |
| AdventHealth Blood & Marrow Transplant Center | Orlando | Florida | 32804 | — |
| Tampa General Hospital | Tampa | Florida | 33606 | — |
| Emory Winship Cancer Institute | Atlanta | Georgia | 30322 | — |
| University of Illinois | Chicago | Illinois | 60612 | — |
| University of Chicago | Chicago | Illinois | 60637 | — |
| University of Louisville Health Brown Cancer Center | Louisville | Kentucky | 40202 | — |
| Norton Cancer Institute, St. Matthews Campus | Louisville | Kentucky | 40207 | — |
| Beth Israel Deaconess Medical Center | Boston | Massachusetts | 02215 | — |
| University of Michigan | Ann Arbor | Michigan | 48109 | — |
| Allina Health Cancer Institute | Minneapolis | Minnesota | 55407 | — |
| Washington University School of Medicine | St Louis | Missouri | 63110 | — |
| Institution name: Northwell Health-Brany | Lake Success | New York | 11042 | — |
| Memorial Sloan Kettering Cancer Center | New York | New York | 10065 | — |
| University of Rochester Medical Center | Rochester | New York | 14642 | — |
| SUNY Upstate Medical University | Syracuse | New York | 13210 | — |
| East Carolina University | Greenville | North Carolina | 27834 | — |
| Atrium Health Wake Forest Baptist Medical Center | Winston-Salem | North Carolina | 27157 | — |
| Cleveland Clinic Foundation | Cleveland | Ohio | 44195 | — |
| Oregon Health and Science University- Center for Hematologic Malignancies | Portland | Oregon | 97239 | — |
| UPMC Hillman Cancer Center | Pittsburgh | Pennsylvania | 15232 | — |
| MUSC Hollings Cancer Center (HCC) | Charleston | South Carolina | 29425 | — |
| Baylor University Medical Center | Dallas | Texas | 75246 | — |
| The University of Texas, MD Anderson Cancer Center | Houston | Texas | 77030 | — |
| LDS Hospital - Intermountain Healthcare | Salt Lake City | Utah | 84143 | — |
| West Virginia University | Morgantown | West Virginia | 26506 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 20 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06226571, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 16, 2026 · Synced Oct 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT06226571 live on ClinicalTrials.gov.